CA2435958A1 - Pyrimidine compounds and methods for making and using the same - Google Patents

Pyrimidine compounds and methods for making and using the same Download PDF

Info

Publication number
CA2435958A1
CA2435958A1 CA002435958A CA2435958A CA2435958A1 CA 2435958 A1 CA2435958 A1 CA 2435958A1 CA 002435958 A CA002435958 A CA 002435958A CA 2435958 A CA2435958 A CA 2435958A CA 2435958 A1 CA2435958 A1 CA 2435958A1
Authority
CA
Canada
Prior art keywords
groups
compound
compounds
aryl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002435958A
Other languages
English (en)
French (fr)
Inventor
Aleem Gangjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duquesne University of the Holy Spirit
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2435958A1 publication Critical patent/CA2435958A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002435958A 2001-02-01 2002-01-23 Pyrimidine compounds and methods for making and using the same Abandoned CA2435958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/775,064 2001-02-01
US09/775,064 US6423720B1 (en) 2001-02-01 2001-02-01 Pyrimidine compounds and methods for making and using the same
PCT/US2002/002358 WO2002060450A1 (en) 2001-02-01 2002-01-23 Pyrimidine compounds and methods for making and using the same

Publications (1)

Publication Number Publication Date
CA2435958A1 true CA2435958A1 (en) 2002-08-08

Family

ID=25103214

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002435958A Abandoned CA2435958A1 (en) 2001-02-01 2002-01-23 Pyrimidine compounds and methods for making and using the same

Country Status (6)

Country Link
US (2) US6423720B1 (cg-RX-API-DMAC7.html)
EP (1) EP1363637B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004528293A (cg-RX-API-DMAC7.html)
CA (1) CA2435958A1 (cg-RX-API-DMAC7.html)
DE (1) DE60213763D1 (cg-RX-API-DMAC7.html)
WO (1) WO2002060450A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010142027A1 (en) * 2009-06-12 2010-12-16 Socpra - Sciences Et Genie S. E. C. Guanine riboswitch binding compounds and their use as antibiotics

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
PT1725540E (pt) 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
US8030319B2 (en) * 2005-02-10 2011-10-04 Duquesne University Of The Holy Ghost Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2 3-d]pyrimidines
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
AU2006286576B2 (en) * 2005-09-01 2012-06-14 F. Hoffmann-La Roche Ag Diaminopyrimidines as P2X3 and P3X2/3 modulators
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504765A (ja) 1992-12-16 1996-05-21 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖性の置換5−チアピリミジノンおよび5−セレノピリミジノン化合物
EP0986252B1 (en) * 1993-06-04 2006-03-08 Sarnoff Corporation System and method for electronic image stabilization
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
EP0697788A3 (en) * 1994-08-19 1997-03-26 Eastman Kodak Co Adaptive and global motion compensated cancellation of the interlacing of successive video images with post-processing
US5973733A (en) * 1995-05-31 1999-10-26 Texas Instruments Incorporated Video stabilization system and method
EP0868815A2 (en) * 1996-10-24 1998-10-07 Koninklijke Philips Electronics N.V. Noise filtering
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
JP4389371B2 (ja) * 2000-09-28 2009-12-24 株式会社ニコン 画像修復装置および画像修復方法
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010142027A1 (en) * 2009-06-12 2010-12-16 Socpra - Sciences Et Genie S. E. C. Guanine riboswitch binding compounds and their use as antibiotics
US9993491B2 (en) 2009-06-12 2018-06-12 Socpra—Sciences Et Génie S.E.C. Guanine riboswitch binding compounds and their use as antibiotics

Also Published As

Publication number Publication date
EP1363637A1 (en) 2003-11-26
EP1363637B1 (en) 2006-08-09
JP2004528293A (ja) 2004-09-16
WO2002060450A1 (en) 2002-08-08
US6423720B1 (en) 2002-07-23
EP1363637A4 (en) 2005-04-06
US20030040524A1 (en) 2003-02-27
DE60213763D1 (de) 2006-09-21

Similar Documents

Publication Publication Date Title
Mokale et al. Synthesis and anti-inflammatory activity of some 3-(4, 6-disubtituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidin-5-yl) propanoic acid derivatives
CA2474211C (en) Antiproliferative quinazolines
CH620925A5 (cg-RX-API-DMAC7.html)
Liu et al. Synthesis and antitumor activity of 4-and 5-substituted derivatives of isoquinoline-1-carboxaldehyde thiosemicarbazone
US6423720B1 (en) Pyrimidine compounds and methods for making and using the same
Agrawal et al. Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone
CA2775354A1 (en) Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase
Badawey et al. Benzimidazole condensed ring systems. XI. Synthesis of some substituted cycloalkyl pyrido [1, 2-a] benzimidazoles with anticipated antineoplastic activity
CZ283281B6 (cs) Způsob přípravy v poloze 5 substituovaných pyrrolo(2,3-d)pyrimidinů
Holla et al. Studies on arylfuran derivatives: part VII. Synthesis and characterization of some Mannich bases carrying halophenylfuryl moieties as promising antibacterial agents
US6043228A (en) O6 -substituted guanine derivatives, a process for their preparation and their use in treating tumor cells
Gangjee et al. Synthesis of classical and nonclassical 2‐amino‐4‐oxo‐6‐benzylthieno‐[2, 3‐d] pyrimidines as potential thymidylate synthase inhibitors
EP0068407A1 (en) Aminosulfonylbenzoic acid derivatives
O'Brien et al. Pyrimidines. XVIII. 2, 4-Diamino-5-nitro-6-arylaminopyrimidines. Nitration Study of 2, 4-Diamino-6-chloropyrimidine and a Literature Correction1
US5990118A (en) Purine compounds and xanthine oxidase inhibitors
Parmar et al. Anticonvulsant activity and inhibition of respiration in rat brain homogenates by substituted oxadiazoles
US12128016B2 (en) Vanin-1 inhibitor
US3957766A (en) Novel nitrofuran compounds and pharmaceutical compositions
Jonak et al. Effect of the substituent at C-6 on the biological activity of 2, 4-diamino-5-(1-adamantyl) pyrimidines
Lewis et al. The preparation and antitumor activity of certain derivatives of 6-mercaptopurine
Meena et al. Biologically active sulfonamides moiety: Synthesis, antimicrobial and antimalarial activity
Kornev et al. Reactions of chromone-3-carboxamides with 2-cyanothioacetamides
EP3950064A1 (en) Thymine nucleobase-based triazolopyrimidines and production method therefor
Basyouni et al. Synthesis and Antioxidant Activity of Some Thiazoles, Thiazolidinone, and Thiazolo [5, 4-d] pyrimidine Derivatives
Gangjee et al. Synthesis of three carbon atom bridged 2, 4‐diaminopyrrolo [2, 3‐d]‐pyrimidines as nonclassical dihydrofolate reductase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued